Table 3.
Cardiometabolic medications showing significant protective associations (limited to FDR < 0.05) within time windows of 6, 12, and 24 months.
| Window | Model | ATC Code | OR | conf.low | conf.high | p | FDR.BH | Full Name |
|---|---|---|---|---|---|---|---|---|
| 1 year | C | A10BA | 0.67 | 0.51 | 0.88 | 4.01 × 10−3 | 1.11 × 10−2 | Biguanides |
| 2 years | C | A10BA | 0.68 | 0.52 | 0.90 | 5.79 × 10−3 | 1.68 × 10−2 | Biguanides |
| 0.5 year | F | C07AB | 0.78 | 0.68 | 0.89 | 3.56 × 10−4 | 7.40 × 10−3 | Beta blocking agents, selective |
| 1 year | F | C07AB | 0.80 | 0.70 | 0.91 | 7.59 × 10−4 | 1.29 × 10−2 | Beta blocking agents, selective |
| 2 years | F | C07AB | 0.78 | 0.69 | 0.88 | 9.10 × 10−5 | 2.15 × 10−3 | Beta blocking agents, selective |
| 1 year | C | C08CA | 0.76 | 0.64 | 0.90 | 1.31 × 10−3 | 4.23 × 10−3 | Dihydropyridine derivatives |
| 2 years | C | C08CA | 0.78 | 0.66 | 0.92 | 3.27 × 10−3 | 1.11 × 10−2 | Dihydropyridine derivatives |
| 0.5 year | A | C09AA | 0.68 | 0.53 | 0.87 | 2.11 × 10−3 | 1.43 × 10−2 | ACE inhibitors, plain |
| 0.5 year | C | C09AA | 0.75 | 0.62 | 0.91 | 3.15 × 10−3 | 6.48 × 10−3 | ACE inhibitors, plain |
| 0.5 year | G | C09AA | 0.68 | 0.56 | 0.83 | 1.13 × 10−4 | 1.54 × 10−3 | ACE inhibitors, plain |
| 1 year | A | C09AA | 0.68 | 0.54 | 0.86 | 1.15 × 10−3 | 1.03 × 10−2 | ACE inhibitors, plain |
| 1 year | C | C09AA | 0.61 | 0.51 | 0.74 | 1.59 × 10−7 | 1.25 × 10−6 | ACE inhibitors, plain |
| 1 year | D | C09AA | 0.57 | 0.36 | 0.92 | 2.22 × 10−2 | 4.31 × 10−2 | ACE inhibitors, plain |
| 1 year | E | C09AA | 0.79 | 0.72 | 0.88 | 1.40 × 10−5 | 8.63 × 10−5 | ACE inhibitors, plain |
| 1 year | G | C09AA | 0.71 | 0.59 | 0.85 | 2.80 × 10−4 | 4.00 × 10−3 | ACE inhibitors, plain |
| 2 years | A | C09AA | 0.67 | 0.54 | 0.84 | 5.87 × 10−4 | 1.10 × 10−2 | ACE inhibitors, plain |
| 2 years | C | C09AA | 0.63 | 0.53 | 0.75 | 2.84 × 10−7 | 2.60 × 10−6 | ACE inhibitors, plain |
| 2 years | E | C09AA | 0.81 | 0.73 | 0.90 | 5.38 × 10−5 | 3.41 × 10−4 | ACE inhibitors, plain |
| 2 years | G | C09AA | 0.71 | 0.59 | 0.85 | 1.40 × 10−4 | 2.81 × 10−3 | ACE inhibitors, plain |
| 1 year | C | C09CA | 0.68 | 0.54 | 0.85 | 7.58 × 10−4 | 2.61 × 10−3 | Angiotensin II receptor blockers, plain |
| 1 year | G | C09CA | 0.69 | 0.55 | 0.87 | 1.95 × 10−3 | 1.85 × 10−2 | Angiotensin II receptor blockers, plain |
| 2 years | C | C09CA | 0.73 | 0.58 | 0.90 | 3.97 × 10−3 | 1.25 × 10−2 | Angiotensin II receptor blockers, plain |
| 2 years | G | C09CA | 0.72 | 0.58 | 0.90 | 3.93 × 10−3 | 4.80 × 10−2 | Angiotensin II receptor blockers, plain |
| 0.5 year | A | C10AA | 0.57 | 0.47 | 0.68 | 3.37 × 10−9 | 8.37 × 10−8 | HMG CoA reductase inhibitors |
| 0.5 year | C | C10AA | 0.79 | 0.68 | 0.91 | 1.20 × 10−3 | 2.63 × 10−3 | HMG CoA reductase inhibitors |
| 0.5 year | E | C10AA | 1.14 | 1.05 | 1.24 | 1.64 × 10−3 | 4.26 × 10−3 | HMG CoA reductase inhibitors |
| 0.5 year | G | C10AA | 0.66 | 0.57 | 0.76 | 2.55 × 10−8 | 9.03 × 10−7 | HMG CoA reductase inhibitors |
| 1 year | A | C10AA | 0.50 | 0.42 | 0.60 | 2.87 × 10−13 | 5.17 × 10−11 | HMG CoA reductase inhibitors |
| 1 year | C | C10AA | 0.49 | 0.42 | 0.57 | 2.97 × 10−21 | 7.42 × 10−20 | HMG CoA reductase inhibitors |
| 1 year | D | C10AA | 0.50 | 0.34 | 0.74 | 5.28 × 10−4 | 1.57 × 10−3 | HMG CoA reductase inhibitors |
| 1 year | E | C10AA | 0.83 | 0.77 | 0.91 | 1.69 × 10−5 | 1.00 × 10−4 | HMG CoA reductase inhibitors |
| 1 year | G | C10AA | 0.63 | 0.54 | 0.73 | 4.15 × 10−10 | 2.77 × 10−8 | HMG CoA reductase inhibitors |
| 2 years | A | C10AA | 0.49 | 0.40 | 0.58 | 1.55 × 10−14 | 3.19 × 10−12 | HMG CoA reductase inhibitors |
| 2 years | C | C10AA | 0.49 | 0.43 | 0.57 | 7.09 × 10−21 | 2.60 × 10−19 | HMG CoA reductase inhibitors |
| 2 years | D | C10AA | 0.50 | 0.34 | 0.74 | 4.38 × 10−4 | 1.63 × 10−3 | HMG CoA reductase inhibitors |
| 2 years | E | C10AA | 0.86 | 0.79 | 0.93 | 3.09 × 10−4 | 1.52 × 10−3 | HMG CoA reductase inhibitors |
| 2 years | G | C10AA | 0.63 | 0.54 | 0.72 | 2.65 × 10−10 | 2.92 × 10−8 | HMG CoA reductase inhibitors |
For space limits, only results with FDR < 0.05 are shown. Please refer to Tables S3 and S6 for full results. OR, odds ratio; conf.low, lower 95% CI for OR; conf.high, upper 95% CI for OR; FDR.BH, false discovery rate by the Benjamini–Hochberg method.